Bixiye
QP70-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3) and Lanoxin (digoxin) Injection for Minnesota Health Care Programs Subscribers
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Natiijooyinka Raadinta
Soo bandhiga 2961 - 2970 ee natiijooyinka 4130
Bixiye
QP35-17 Implementation of New Utilization Management Platform
Taariikhda uu dhaqangalayo Barnaamijka: Nov 07, 2017
Bixiye
QP85-18 Pharmacy Benefit Update - New Drug-Related PA with QL Criteria: Pseudobulbar Affect (PBA)
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2018
Bixiye
QP99-18 New FEP Employee Opioid Prescription Requirements
Taariikhda uu dhaqangalayo Barnaamijka: Nov 28, 2018
Bixiye
QP66-18 Pharmacy Benefit Update - New Drug-Related Prior Authorization with Quantity Limit Criteria: Noctiva (desmopressin acetate)
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP16-17 Contract Renewal Overlapping with Termination Notices for Interpreter Agencies
Taariikhda dhaqangalka Barnaamijka: Jul 20, 2017
Bixiye
QP20-17 Searching Eligibility and Benefits
Taariikhda barnaamijka Dhaqangalayso Agosto 08, 2017
Bixiye
QP68-18 Site of Care Drug Infusion/Injection Program
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018
Bixiye
QP61-18 Availity Authorization Training with Live Demo
Taariikhda barnaamijka Dhaqangalayso Agosto 06, 2018
Bixiye
QP67-18 Pharmacy Benefit Exclusion for Alferon N (interferon alpha-n3), Cytovene (ganciclovir), Foscarvir (foscarnet), Prevymis (letermovir), Trogarzo (ibalizu,ab-uiyk), Vistide (cidofovir) and Zovirax (actclovir)
Taariikhda barnaamijka Dhaqangalayso Agosto 21, 2018